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Our body is made up of over thirty trillion (3 x 1013) cells, all contributing to the 
homeostastic mechanisms that are in place to ensure our health.1 To allow the different 
cells to function, we have five liters of blood in our body, containing different cell 
types that fulfill several important roles, namely: oxygen and carbon dioxide transport 
(erythrocytes/red blood cells), thrombosis (thrombocytes/platelets) and protection 
against pathogens (leukocytes/white blood cells). All blood cells are derived from 
a multipotent progenitor cell, known as the hematopoietic stem cell (HSC). HSCs 
have long-term self-renewal capacity, and through several differentiation steps these 
cells give rise to the various blood cell lineages. Early in HSC differentiation, two 
branches can be identified, with the myeloid progenitor and lymphoid progenitor at 
the top of the respective lineages. Hematopoiesis during embryonic development 
mainly takes place in the fetal liver and spleen, before the bone marrow becomes 
the permanent site of blood cell production, approximately 2 months before birth.2 
Leukemia is the abnormal proliferation of immature (and therefore non-functional) 
white blood cells. Leukemia progression can be rapid and aggressive, in which case 
it is referred to as acute leukemia. Cell proliferation and disease progression can 
also be more protracted, in which case it is known as chronic leukemia. As leukemia 
progresses, the immature blood cells suppress normal haematopoiesis, resulting in 
anemia, thrombocytopenia, and impairment of the immune system. Two general 
acute leukemia subtypes are differentiated, depending on the lineage, namely acute 
myeloid leukemia and acute lymphoblastic leukemia. The majority of childhood 
leukemias are of the acute lymphoblastic type (ALL), with approximately 125 newly 
diagnosed cases each year in the Netherlands. While lymphoblastic leukemias can be 
subdivided in B-cell derived and T-cell derived leukemia, the majority of childhood 
ALL patients are diagnosed with B-cell precursor (BCP) acute lymphoblastic 
leukemia or B-ALL. Over the past decades the treatment of childhood B-ALL 
has vastly improved through use of general chemotherapeutics, better scientific 
understanding of the disease, and stratification of patient risk groups, going from 
<10% survival chance in the 1960s to ~90% survival nowadays.3 However, this 
tremendous bettering has not led to similar prognoses for the youngest childhood 
ALL patients: i.e. infants or children < 1 year of age. 
MLL-rearranged infant ALL
In the Netherlands, around 5 infants are diagnosed with ALL each year. The majority 
(~80%) of infant ALL cases are characterized by chromosomal rearrangements 
involving the Mixed Lineage Leukemia (MLL) gene, also known as Lysine-Specific 
Methyltransferase 2A (KMT2A), which fuse part of the MLL gene to part of one 
of its translocation partner genes.4 Although as many as 80 different fusion partner 
genes have been identified, most MLL-rearranged infant ALL cases involve MLL 
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being fused to AF4 (~50%), AF9 (~20%) or ENL (~10%), also referred to as t(4;11), 
t(9;11) and t(11;19) translocations, respectively.5 Interestingly, the long-term event 
free survival (EFS) of infants with germline MLL (i.e. without an MLL translocation) 
is approximately 75%, just below the EFS for ALL in older children.4 However, 
infants with ALL involving an MLL-rearrangement fare significantly worse, with 
EFS rates of approximately 35-45%, independent of MLL fusion partner.4,6-8
The wildtype MLL protein functions as a histone methyl transferase, catalyzing the 
trimethylation of lysine 4 on histone H3, which in turn initiates the formation of the 
transcriptional elongation complex in preparation of active transcription.9,10 MLL 
fulfills a key role in normal haematopoiesis, through regulation of the homeobox 
A (HOXA) gene cluster.11,12 While in healthy cells additional stimuli are required to 
activate RNA polymerase, an MLL fusion protein can circumvent this. Although the 
MLL fusion protein has lost its methyltransferase domain, it has gained the capacity 
to recruit the methyltransferase DOT1L, which in turn dimethylates lysine 79 at 
histone H3, activating transcriptional elongation.13-15 Hence, MLL fusions induce 
disturbed histone methylation and associated enhanced expression of specific genes. 
Interestingly, besides abnormal histone methylation, MLL-rearranged infant ALL 
is also characterized by increased DNA methylation at specific promoter regions, 
thereby suppressing gene expression.16 Together, these perturbations in epigenetic 
machinery result in aberrant gene expression profiles that distinguish MLL-rearranged 
ALL from MLL germline infant ALL and BCP-ALL in older children.17
Leukemia-inducing MLL-rearrangements arise in utero, and while these lesions 
are the common denominator in the majority of infant ALL cases, and predictive 
of poor prognosis, the short latency of the disease has instigated investigation of 
potential secondary oncogenic hits or cooperative drivers.18,19 A recent study into 
the mutational landscape of MLL-rearranged infant ALL revealed an extremely low 
frequency of additional mutations.20 Still, this study confirmed earlier identified 
(sub-clonal) mutations in NRAS and KRAS.21,22 Previously, the presence of (sub-
clonal) RAS mutations had been associated with therapy resistance and an extremely 
dismal prognosis for the MLL-AF4 infant ALL subgroup, with hardly any chance of 
survival.21 The discovery of RAS mutations is especially intriguing, considering the 
frequent increase in FMS-like receptor tyrosine kinase-3 (FLT3) expression in MLL-
rearranged infant ALL, which is coupled to downstream RAS pathway activation as 
well as an inferior prognosis.23,24
Clinical presentation and current therapy
MLL-rearranged ALL cells are characterized by a highly immature pro-B 
immunophenotype, corresponding to the expression of the cell surface markers 
CD34 and CD19, and absence or diminished expression of CD10, and are further 
typically characterized by the expression of certain myeloid markers.25,26 Several 
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clinical features have been identified as predictors for a poor prognosis, including age 
at diagnosis (<6 months), high white blood cell counts, poor glucocorticoid response 
(determined after 8 days of prednisone mono-therapy, prior to induction therapy), 
CD10 negativity, and central nervous system infiltration.4,6,27-29 Additionally, low 
expression of HOXA genes is associated with a poor prognosis.28 Although the 
majority of MLL-rearranged infant ALL patients (~95%) go into remission, ~50% 
of the patients have a relapse (typically within 1 year from diagnosis, while still 
on treatment), resulting in overall survival chances of approximately 50%.4 Present 
international 2-year treatment protocols consist of combination chemotherapy, 
including glucocorticoids (prednisone, dexamethasone), antimetabolites (cytarabine, 
6-mercaptopurine, methotrexate), L-asparaginase, daunorubicin and vincristine. 
A minority of patients at very high risk of relapse undergoes allogeneic stem cell 
transplantation. Given the exceedingly high relapse rate in MLL-rearranged infant 
ALL, current treatment regimes clearly are not sufficient. Therefore, the recent 
research focus has been on the discovery of novel, more targeted therapies to improve 
prognosis. 
Development of targeted therapeutic strategies against MLL-rearranged 
infant ALL
The disturbed epigenetic landscape that characterizes MLL-rearranged infant 
ALL has provided clues into new therapeutic strategies. With DOT1L as one of 
the key components in MLL fusion protein mediated aberrant regulation of gene 
expression,30,31 it is no surprise that inhibitors (EPZ004777 and EPZ-5676) against 
this histone methyltransferase have been developed.32,33 Using connectivity 
mapping, Stumpel et al. discovered that inhibitors of histone deacetylase (HDAC) 
enzymes could reverse aberrant gene expression profiles that define MLL-rearranged 
infant ALL.34 This has led to the identification and characterization of the HDAC 
inhibitor LBH-589 (or panobinostat), which has shown high potency and efficacy 
against MLL-rearranged infant ALL cells in vitro, as well as in vivo in xenograft 
mouse models.35 Additionally, the Bromodomain and Extra-Terminal (BET) family 
of proteins has proven an interesting target for MLL-rearranged infant ALL, as 
BET proteins function as epigenetic “readers” of histone acetylation, and facilitate 
transcription through chromatin remodeling as part of multi-protein complexes.15,36 
Therefore, different BET inhibitors have been investigated as drug candidates, with 
especially I-BET151 showing promising results in MLL-rearranged leukemia cell 
lines, as well as in mouse models.37 The observed increased DNA methylation, and 
promoter hypermethylation more specifically, have further instigated the research 
into demethylating agents, with decitabine and zebularine as effective drugs against 
MLL-rearranged ALL cells.16,38 While these drugs have shown promise as therapeutic 




patient is still a time-consuming process, especially considering the fact that these 
drugs need to be safe and efficacious in adults before the transition can be made to 
pediatric application. Awaiting results from clinical investigation of these previously 
identified therapeutics, this thesis describes the investigation of new therapeutic 
candidates, predominately FDA-approved and off-patent drugs, in order to expedite 
the implementation of potent agents into current therapeutic regimens for MLL-
rearranged infant ALL.
Outline of this thesis
Chapter 2 describes a drug repurposing approach through screening of mainly FDA-
approved and off-patent drugs on different MLL-rearranged infant ALL and BCP-
ALL cell line models. This led to the identification of topoisomerase I inhibitors, 
especially 7-ethyl-10-hydroxycampthotecin (SN-38), as potent inhibitors of MLL-
rearranged infant ALL cells in vitro. Additionally, the efficacy of the SN-38 pro-
drug irinotecan was investigated in vivo using xenograft mouse models of MLL-
rearranged infant ALL.  
In chapter 3, we report the investigation of inhibitors against MLL-rearranged ALL 
cells harboring additional RAS mutations. Hereto, different (approved) inhibitors of 
RAS-pathway components were tested on MLL-rearranged cell line models, as well 
as primary patient material. Among all inhibitors tested in this study, MEK inhibitors 
showed the most promising results. Moreover, since RAS mutations are associated 
with glucocorticoid resistance, we investigated the effect of MEK inhibition on 
the response of MLL-rearranged ALL cells to the glucocorticoid prednisolone, and 
observed glucocorticoid-sensitizing effects. Furthermore, chapter 4 reports the in 
vivo evaluation of trametinib, the most potent MEK inhibitor as found in chapter 3, 
in a xenograft mouse model of RAS mutant MLL-rearranged infant ALL. 
Since MLL-rearranged infant ALL is characterized by aberrant histone methylation 
and DNA methylation, we performed drug screens using two drug libraries consisting 
of epigenetic drugs in chapter 5. S-adenosylhomocysteine hydrolase inhibitors 
potently inhibited MLL-rearranged infant ALL in vitro. Additionally, we investigated 
the mechanism of action of these inhibitors, while also assessing efficacy in an MLL-
rearranged infant ALL xenograft mouse model. 
Finally, the results described in this thesis are discussed and summarized in chapter 
6, and chapter 7 provides a layman’s summary in Dutch. 
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Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with a 
poor clinical outcome, and is characterized by translocations of the Mixed Lineage 
Leukemia (MLL) gene. Previously, we identified RAS mutations in 14-24% of infant 
ALL patients, and showed that the presence of a RAS mutation decreased the surviv-
al chances even further. We hypothesized that targeting the RAS signaling pathway 
could be a therapeutic strategy for RAS-mutant infant ALL patients. Here we show 
that the MEK inhibitors trametinib, selumetinib and MEK162 severely impair pri-
mary RAS-mutant MLL-rearranged infant ALL cells in vitro. While all RAS-mutant 
samples were sensitive to MEK inhibitors, we found both sensitive and resistant 
samples among RAS-wildtype cases. We confirmed enhanced RAS pathway signal-
ing in RAS-mutant samples, but found no apparent downstream over-activation in 
the wildtype samples. However, we did confirm that MEK inhibitors reduced pERK 
levels, and induced apoptosis in the RAS-mutant MLL-rearranged ALL cells. Finally, 
we show that MEK inhibition synergistically enhances prednisolone sensitivity, both 
in RAS-mutant and RAS-wildtype cells. In conclusion, MEK inhibition represents 
a promising therapeutic strategy for MLL-rearranged ALL patients harboring RAS 
mutations, while patients without RAS mutations may benefit through prednisolone 
sensitization.
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Introduction
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an ag-
gressive malignancy, associated with high relapse rates and a poor clinical outcome.75 
The majority (~80%) of these patients carry a leukemia-specific chromosomal trans-
locations involving the Mixed Lineage Leukemia (MLL) gene.75 MLL-rearranged in-
fant ALL patients fare significantly worse than infant ALL patients who do not carry 
MLL translocations, with event-free survival rates of 30-40% vs. ~80%, respective-
ly.4 Recently, we demonstrated that 24% of the infant ALL patients carrying MLL 
translocation t(4;11), the most frequently observed translocation of MLL among 
these patients, also carry a RAS mutation. Mutations in NRAS were found in 11% and 
KRAS mutations in 13% of cases.21 Moreover, we showed that the presence of a RAS 
mutation in MLL-rearranged patients represented an independent predictive factor 
for an even worse clinical outcome in this high-risk group. Nearly all RAS-mutant 
t(4;11)+ infant ALL patients relapsed within the first year from diagnosis, while still 
on treatment, and all died within 4 years from diagnosis.21 
Despite this strong association with an exceedingly poor prognosis, a recent study 
by Emerenciano et al. suggested that RAS mutations in MLL-rearranged infant ALL 
may not act as driver mutations and are not required for disease progression, but 
rather act only at disease onset.22 Yet, our previous data clearly showed that RAS-mu-
tant MLL-rearranged infant ALL patients are at extremely high-risk of therapy fail-
ure and early death. Moreover, RAS pathway inhibition, including MEK inhibition, 
was previously shown to effectively inhibit RAS-mutant MLL-rearranged AML in 
vitro.76,77 Therefore, we decided to investigate the potential of RAS pathway inhibi-
tion and found that RAS-mutant MLL-rearranged ALL cells are remarkably sensitive 
to MEK inhibitors.
Materials & Methods
Patient samples and cell lines
Bone marrow and peripheral blood samples from untreated infant ALL patients were 
collected at the Sophia Children’s Hospital (Rotterdam, The Netherlands) as part of 
the international collaborative INTERFANT treatment protocol.4 Approval for these 
studies was obtained from the Erasmus MC Institutional Review Board. Informed 
consent was obtained according to the Declaration of Helsinki. All samples were 
processed within 24 hours after sampling as described before, with optional removal 
of contaminating non-leukemic cells by immunomagnetic beads, to ensure leukemic 
blast content for all samples was >90%.23 The t(4;11)-rearranged ALL cell line SEM 
and t(11;19)-rearranged ALL cell line KOPN8 were purchased from the German 
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Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), 
while the t(4;11)-rearranged ALL cell line RS4;11 was purchased from The Global 
Biosource Center (ATCC, Middlesex, UK). All cell lines were cultured in suspen-
sion in RPMI-1640 with GlutaMAX (Invitrogen Life Technologies, Waltham, MA, 
USA) supplemented with 10% Fetal Calf Serum, 100 IU/mL penicillin, 100 IU/mL 
streptomycin and 0.125 µg/mL amphotericin B (Invitrogen Life Technologies) at 
37°C under 5% CO
2
 atmosphere. 
In vitro cytotoxicity assay and small molecule inhibitors
The in vitro cytotoxicity of MEK162, selumetinib and Trametinib (MedChem Ex-
press, Stockholm, Sweden) was tested by MTS and MTT assays. All inhibitors were 
weighed, dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C until use. Cy-
totoxicity assay dilutions were prepared in cell culture medium, keeping final DMSO 
concentration <0.5%. Final concentrations of the small molecule inhibitors ranged 
from 50 µM to 0.15 nM, indicated in the respective figures. The in vitro sensitivity 
of cell lines was assessed by using 4-day MTS conversion assays, as described pre-
viously.78 In vitro cytotoxicity of patient cells was assessed by using a 4-day MTT 
conversion assay, as described before.23 Data was normalized to vehicle (DMSO) 
controls.
Western blot
Protein extracts (25 µg) were electrophoretically resolved on pre-cast SDS-poly-
acrylamide gels (anyKD, TGX, Bio-Rad, Veenendaal, The Netherlands) and trans-
ferred to nitrocellulose membranes. Membranes were blocked with 5% bovine 
serum albumin and subsequently probed with antibodies directed against total or 
phosphorylated ERK, MEK, ELK-1, Akt, or p70S6K (Cell Signaling, Danvers, MA, 
USA). Membranes were counterstained with IRDye® 680/800 conjugated second-
ary antibodies (Li/COR, Leusden, The Netherlands) and were scanned by an Odys-
sey imaging system (Li/COR). Membranes were re-probed with mouse monoclonal 
anti-β-actin antibodies (Sigma-Aldrich, St. Louis, MO, USA) as loading control. 
Fluorescence was quantified using the Odyssey 3.0 application software.  
RAS activation
RAS activation was analyzed using the RAS Activation Assay Kit (17-218, Mer-
ck-Millipore, Amsterdam, The Netherlands). Briefly, 1x107 cells were isolated and 
lysed with Mg2+ Lysis Buffer (MLB), and stored at -80°C until use. GST-fused RAF-
1 RAS-binding domain (RBD) bead slurry was added to the lysate and incubated 
for 1 hour at 4°C while agitating. Beads were isolated by centrifugation and washed 
with MLB, and precipitated protein was denatured with Laemmli buffer at 95°C 
before immunoblotting. As a positive control, total cell lysate was included in the 
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immunoblotting procedure. The provided RAS antibody (05-516, Merck-Millipore) 
was used, and GST (Cell Signaling) and β-actin (Sigma-Aldrich) antibodies were 
used as loading controls for the beads and total protein, respectively. Fluorescence 
was quantified using the Odyssey 3.0 application software. 
Annexin-V/7-AAD apoptosis and cell cycle assays 
For assessment of early and late apoptosis, the PE Annexin-V Apoptosis Detection 
Kit (BD Pharmingen, Breda, The Netherlands) was used according to the manufac-
turer’s protocol. Briefly, drug-exposed cells were isolated, washed with PBS and 
re-suspended in binding buffer. Cells were stained with PE Annexin V and/or 7-AAD 
for 15 minutes, and sorted using fluorescence activated cell sorting (FACS). Cell cy-
cle progression was assessed by permeabilization of isolated cells through hypotonic 
lysis. Subsequently, RNAse treatment was performed, and DNA was stained using 
propidium iodide, after which FACS determined DNA content. Data was analyzed 
using FlowJo software (FlowJo, Ashland, OR, USA).
Gene expression data
Recently published gene expression data (Affymetrix HU133plus2.0) for part of 
the t(4;11)+ patient samples was available (i.e. for 6 of 9 MEK inhibitor resistant 
RAS-wildtype samples, 4 of 5 sensitive RAS-wildtype samples and 3 of 6 RAS-mutant 
samples).28 This data is available in GEO database19 (accession number GSE19475) 
and was acquired as previously described.28 Tyrosine kinase receptor expression 
was derived from this dataset, using the following probe sets: 206674_at (FLT3), 
204406_at (VEGFR-1), 203934_at (VEGFR-2), 234379_at (VEGFR-3), 210973_s_
at (FGFR-1), 208225_at (FGFR-2), 204380_s_at (FGFR-3), 204579_at (FGFR-
4), 211551_at (EGFR), 210930_s_at (ERBB2), 226213_at (ERBB3), 214053_at 
(ERBB4), 205463_s_at (PDGFR-A), 217112_at (PDGFR-B), 204891_s_at (Lck) 
and 213324_at (Src).
Statistical analysis
Statistical analyses were performed with SPSS Statistics version 17.0 (SPSS Inc. 
Chicago, IL, USA). All tests were two-tailed and p-values < 0.05 were consid-
ered significant. The effect of combining drugs (i.e. synergy, additivity or antago-
nism) was assessed using Berenbaums criteria, as previously described.79,80 Briefly, 
we calculated the Synergy Factor (FSyn) with the formula FSyn = ([Drug Xin combina-
tion with Y
]/[Drug X]) + ([Drug Y
in combination with X
] / [Drug Y]) for a particular fraction-
al effect.  If the drug combination results in F
Syn 




RAS-mutant MLL-rearranged ALL cells are sensitive to MEK inhibition
Since the previously identified RAS aberrations are all activating mutations (at res-
idues G12, G13 or Q61), we wondered whether small molecule inhibitors targeting 
RAS pathway components could suppress RAS-mutant leukemic cells.21,81 Therefore, 
7 RAS pathway inhibitors, already approved for therapeutical use or under clini-
cal investigation for other malignancies with RAS pathway mutations, were select-
ed as therapeutic strategies for the RAS-mutant infant ALL patients. Using 4-day 
MTS cell viability assays we tested the in vitro anti-leukemic potential of salirasib 
(RAS localization inhibitor), vemurafenib (BRAF inhibitor), sorafenib (pan-kinase 
inhibitor), trametinib, selumetinib and MEK162 (MEK inhibitors) and temsirolim-
us (mTOR inhibitor) against RAS-mutant MLL-rearranged ALL cell line KOPN8, 
and the RAS-wildtype MLL-rearranged cell lines SEM and RS4;11. Interestingly, the 
RAS-mutant cell line KOPN8 was more sensitive to the MEK inhibitors MEK162, 
selumetinib and trametinib (Fig.1). Temsirolimus and sorafenib potently reduced cell 
viability of both RAS-mutant and RAS-wildtype cell lines. Additionally, salirasib and 
vemurafenib did not substantially reduce cell viability, even at high concentrations 
(>10µM). To confirm the efficacy of these inhibitors, we performed 4-day MTT cell 
viability assays on primary diagnostic RAS-mutant (n=6) and RAS-wildtype (n=14) 
t(4;11)+ infant ALL samples. Interestingly, compared to RAS-wildtype t(4;11)+ ALL 
cases, the RAS-mutant t(4;11)+ infant ALL cases were significantly more sensitive 
to all MEK inhibitors (Fig.2A) with median IC
50
 values of <0.1 mM for MEK162 
and selumetinib and <0.01 mM for trametinib (Fig.2B). Additionally, all other test-
ed inhibitors (salirasib, temsirolimus, sorafenib and vemurafenib) reached only IC
50
 
values of >10µM (Sup.Fig.1).
Also, we included one matched pair of diagnostic/relapse t(4;11)+ samples. For this 
particular patient, no RAS mutation was present at diagnosis, but a RAS mutation 
could be identified at relapse. Indeed, the RAS-mutant relapse sample of this patient 
was more sensitive to all three MEK inhibitors tested than the RAS-wildtype diag-
nostic sample (Fig.2B). 
Enhanced RAS activation in t(4;11)+ infant ALL cells carrying RAS mu-
tations  
The MEK inhibitors MEK162, selumetinib and trametinib significantly reduce via-
bility of RAS-mutant MLL-rearranged ALL cells. Notably, a subset of the RAS-wild-
type primary t(4;11)+ infant ALL samples also responded favorably to the MEK in-
hibitors (Fig.2B). We wondered whether other biomarkers, besides RAS mutation 
status, could predict MEK inhibitor sensitivity in MLL-rearranged ALL. Wildtype 
RAS proteins are under regulation of upstream signaling events, often involving ty-
47
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Figure 1. MEK inhibitors specifically impede RAS-mutant MLL-rearranged ALL cell line 
KOPN8. Cell viability of MLL-rearranged cell lines exposed to MEK162, selumetinib, trametinib, 
temsirolimus, sorafenib, salirasib and vemurafenib. All cell lines respond to sorafenib and temsirolim-
us, while RAS-mutant KOPN8 (solid line) is more sensitive than RAS-wildtype SEM (large dashed line) 
or RS4;11 (small dashed line). Data are represented as mean +/- sem. n≥3.
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rosine kinase receptors, while mutant RAS proteins are less dependent on upstream 
activation due to reduced GTPase activity, rendering a surplus of activated GTP-
bound RAS. Therefore, we determined the RAS protein levels and RAS activity 
in our primary t(4;11)+ infant ALL cells. No significant difference in RAS protein 
levels was observed between the RAS-mutant and RAS-wildtype t(4;11)+ infant ALL 
samples using Western blot analysis (Fig.3A). Next, we investigated the level of 
active (GTP-bound) RAS in these samples by precipitation with RAF-1 RAS inter-
action protein, followed by immunoblotting. As expected, the RAS-mutant t(4;11)+ 
infant ALL samples showed significant (p=0.013) higher levels of RAS activation 
as compared to RAS-wildtype samples (Fig.3B). No differences in RAS activation 
were observed between RAS-wildtype samples that were sensitive or resistant to 
MEK inhibition. 
Subsequently, we determined phosphorylation levels of MEK (pMEK) and ERK 
(pERK) by immunoblotting (Sup.Fig.2A and B, respectively). Quantification of the 
blots indicated a significantly higher level of pMEK in our RAS-mutant samples, 
compared to RAS-wildtype samples (p=0.0312, Fig.3C), although there was no dif-
ference in pMEK levels between the MEK inhibitor resistant and sensitive RAS-wild-
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Figure 2. Primary RAS-mutant MLL-rearranged ALL cells are sensitive to MEK inhibitors. (A) 
Patient derived t(4;11)+ infant ALL cells exposed to MEK inhibitors indicate RAS-mutant samples 
(solid line, n=6) are more sensitive compared to RAS-wildtype samples (dashed line, n=14). Data are 
represented as median +/- sd. *0.01<p<0.05; **0.001<p<0.01; ***p<0.001. (B) The IC50 (concentra-
tion needed to inhibit 50% of the leukemic cell viability) of the individual t(4;11)+ infant ALL patient 
samples shown in (A). Median IC50 values, represented by horizontal bars, confirm strong sensitivity 
of RAS-mutant patient samples compared to the majority of RAS-wildtype samples. Open circles indi-
cate matched diagnosis (wildtype) and relapse (mutant) samples. The tick lines indicate separation be-
tween MEK inhibitor sensitive and resistant patient samples (IC50<1μM and IC50>1μM, respectively).
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compared to its matched wildtype diagnosis sample. Additionally, no differences in 
pERK levels were found between RAS-wildtype and RAS-mutant samples (Fig.3D), 
nor between RAS-wildtype cells that were sensitive or resistant to MEK inhibition. 
In MLL-rearranged AML, MEK inhibitor resistance can occur through activation 
of tyrosine kinase receptor (TKR) signaling (i.e. involving VEGFR-2).76 Further-
more, we previously found MLL-rearranged ALL is characterized by high expression 
of Fms-like tyrosine kinase 3 (FLT3).23 Therefore, we interrogated available gene 
expression profiles of primary samples for possible differences in TKR expression 
levels between the MEK inhibitor sensitive and resistant subgroups (Sup.Fig.3). In-
terestingly, apart from FLT3, expression of TKRs is relatively low in the different 
patient samples. Surprisingly, FGFR-1 expression is significantly lower in MEK in-
hibitor resistant RAS-wildtype samples (p=0.02), while there are no significant dif-
ferences in expression of FLT3, VEGFR (1-3), FGFR (2-4), EGFR and ERBB (2-4), 



















































































Figure 3. RAS-mutant t(4;11)+ 
ALL cells have enhanced 
downstream activation. (A) 
RAS protein level, relative to 
β-actin, determined by western 
blotting in t(4;11)+ infant ALL 
samples, subdivided according 
to RAS mutation status (WT or 
MUT) and MEK inhibitor sen-
sitivity (resistant (Res) and sen-
sitive (Sens)). No differences in 
median protein level (horizontal 
bars) are observed between the 
different subgroups. (B) Rela-
tive RAS activation is enhanced 
in RAS-mutant t(4;11)+ patient 
samples, though no difference 
is observed between the MEK 
inhibitor resistant and sensi-
tive RAS-wildtype subgroups. 
(C) Ratio phosphorylated MEK 
(pMEK)/total MEK in RAS-mu-
tant (MUT) and RAS-wildtype 
(WT) t(4;11)+ infant ALL sam-
ples shows increased MEK acti-
vation in RAS-mutant samples, while the MEK inhibitor resistant and sensitive RAS-wildtype samples 
have comparable MEK activation. (D) Ratio phosphorylated ERK (pERK)/total ERK in RAS-mutant 
and RAS-wildtype t(4;11)+ infant ALL samples shows no significant differences in ERK activation 
between subgroups. Horizontal bars present group medians. Open circles indicate matched diagnosis 
(wildtype) and relapse (mutant) samples. *p<0.05.
50
Chapter 3
MEK inhibition results in reduced ERK phosphorylation 
Next, we exposed MLL-rearranged ALL cell lines SEM and KOPN8 to the MEK 
inhibitors (selumetinib, MEK162 and trametinib) and determined pERK and pMEK 
levels by immunoblotting (Fig.4). Interestingly, pERK levels were drastically re-
duced in both SEM and KOPN8, already after 6 hours of exposure, and this effect 
was sustained for at least 48 hours, regardless of the inhibitor used (Fig.4A). Fur-
thermore, prolonged exposure (24 and 48 hours) to the MEK inhibitors selumetinib 
and MEK162 resulted in an increase of pMEK in SEM and KOPN8 (Fig.4B). Addi-
tionally, we determined phosphorylation of ERKs downstream effector ELK-1, but 
ELK-1 activation was not influenced by MEK inhibition (Sup.Fig.4A). 
Since SEM cells responded modestly to MEK inhibition but did show a significant 
loss of pERK levels, we investigated whether these cells could circumvent loss of 
ERK activation by upregulating RAS-mediated PI3K-Akt-mTOR signaling. There-
















Figure 4. MEK inhibition results in reduced ERK phosphorylation. (A) Western blot analysis of 
SEM and KOPN8 (upper and lower panels, respectively) exposed to 500 nM of MEK inhibitor or vehi-
cle control (DMSO) for 6, 24 and 48 hours. Both cell lines almost completely lose ERK phosphoryla-
tion (pERK), while total ERK (ERK) levels remain unaffected. (B) Analysis of MEK phosphorylation 
(pMEK) suggests exposure to MEK162 and selumetinib results in enhanced MEK phosphorylation in 
both cell lines, whereas total MEK (MEK) levels remain constant.
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fore, the downstream phosphorylation of Akt (Ser437) and p70S6K (Thr389) was 



















































































































































Figure 5. MEK inhibitors induce apoptosis. (A,B) Early apoptosis (percentage AnnexinV single 
positive of total) of SEM and KOPN8 cells (respectively) after exposure to DMSO vehicle (white 
bars) or 500 nM MEK162, selumetinib or trametinib (light grey, dark grey and black bars, respective-
ly), indicates MEK inhibition slightly induces early apoptosis. Data are represented as mean +/- sem. 
n=3. (C,D) Late apoptosis (percentage AnnexinV and 7-AAD double positive cells of total) of SEM 
and KOPN8 (respectively) show that while SEM cells have no induction of late apoptosis in response 
to MEK inhibition, compared to the DMSO controls, KOPN8 clearly undergoes apoptosis, especially 
after prolonged exposure (>48 hours). Data are represented as mean +/- sem. n=3. (E,F) Cell cycle 
analysis of SEM and KOPN8 (respectively) after 96 hours exposure to vehicle (DMSO) or 500 nM 
MEK162, selumetinib or trametinib indicates MEK inhibition does not impinge on the cell cycle pro-
gression. Stacked bar graph indicates percentage of cells in G0/G1 (black), S (grey) and G2/M (white) 
cell cycle stages. Data are represented as mean +/- sem. n=3.
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ylation were observed in response to MEK inhibitor exposure (Sup.Fig.4B and C, 
respectively). 
MEK inhibitors induce apoptosis 
Subsequently, we investigated the phenotypic effects of the MEK inhibitors on SEM 
and KOPN8 through analysis of early and late apoptosis markers (Annexin-V and 
7-AAD, respectively), using flow-cytometry. Interestingly, both RAS-wildtype SEM 
and RAS-mutant KOPN8 undergo early apoptosis, after treatment with MEK inhib-
itor (Fig.5A and B, respectively). However, while late apoptosis is barely observed 
for SEM (Fig.5C), late apoptosis in MEK inhibitor exposed KOPN8 cells is en-
hanced substantially, especially after prolonged exposure (Fig.5D), suggesting the 
response to MEK inhibition is characterized by increased apoptosis. Furthermore, 
MEK inhibitor exposure induced protein levels of pro-apoptotic BIM, most evident-
ly for KOPN8, while p53 levels remained unaffected (Sup.Fig.5). Additionally, we 
investigated cell cycle progression under influence of MEK inhibition. Interestingly, 
no considerable differences in SEM or KOPN8 cell cycle progression are observed 
after 96 hours exposure to MEK162, selumetinib or trametinib (Fig.5E and F, re-
spectively), nor after exposure for 24, 48 and 72 hours (Sup.Fig.6A-B, C-D and E-F, 
respectively).   
MEK inhibition enhances prednisolone sensitivity 
In our previous study, we found that MLL-rearranged infant ALL patient samples 
harboring RAS mutations are more resistant to prednisolone.21 Therefore, we exam-
ined whether inhibition of MEK could enhance prednisolone sensitivity of RAS-mu-
tant cells. As shown in Figure 6A, prednisolone alone decreases cell viability of 
SEM cells to only ~50%. Interestingly, while trametinib by itself induces only minor 
cell viability decrease in SEM cells (Fig.6B), the combination of trametinib and 
prednisolone greatly enhanced the efficacy of prednisolone, especially at high-
er concentrations (Fig.6A). The combination of prednisolone and trametinib also 
strongly decreased cell viability in KOPN8 more potently than either drug alone; 
low concentrations of trametinib nearly eradicated all KOPN8 cells that did not re-
spond to prednisolone treatment (Fig.6C). A similar sensitizing effect was observed 
when exposing SEM and KOPN8 to MEK162 or selumetinib in combination with 
prednisolone (Sup.Fig.7A-D and F-I, respectively). Since trametinib alone already 
effectively decreases viability of KOPN8 cells (Fig.6D), we quantified the combi-
natorial effect of MEK inhibitors and prednisolone using the synergy factor (FSyn) 
calculation, as previously described.79,80 The plot in Figure 6E shows the fractional 
effect (i.e. the relative decrease of cell viability) induced by the combination of tra-
metinib with prednisolone, and the corresponding Synergy Factor. Interestingly, in 
both SEM and KOPN8 cells we observed FSyn values < 0.5, indicating strong synergy 
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between trametinib and prednisolone. Also combining MEK162 or selumetinib with 
prednisolone resulted in moderate to strong synergistic effects (Sup.Fig.7E and J, 
respectively). Additionally, we investigated whether this enhanced effect was related 
to differential expression of the glucocorticoid receptor (GR), the target of prednis-
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Figure 6. MEK inhibition enhances pred-
nisolone sensitivity. (A) Dose-response 
curves of the SEM cell line exposed to pred-
nisolone alone (black curve) or in combina-
tion with 0.04 μM, 0.2 μM, 1 μM or 5 μM 
trametinib (red, blue, green and grey curves, 
respectively). Low concentrations of trame-
tinib particularly sensitize cells that escape 
high concentrations of prednisolone. Data 
are represented as mean +/- sem. n=3. (B) 
Response of SEM to the single trametinib 
concentrations used in A. n=3. (C) Dose-re-
sponse curves of KOPN8 treated with prednisolone (black curve), or in combination with the afore-
mentioned trametinib concentrations (shown in red, blue, green and grey, respectively). KOPN8 cells 
are also sensitized towards prednisolone by co-exposure with low concentrations of trametinib. Data 
are represented as mean +/- sem. n=3 (D) KOPN8 exposed to single trametinib concentrations. Data 
are represented as mean +/- sem. n=3. (E) Combined exposure to prednisolone and trametinib (merged 
data from 3 separate experiments) was quantified using FSyn calculations (FSyn<1 indicates synergy) 
and plotted against fractional effect (i.e. inhibition of cell viability). In SEM (red) moderate to strong 
synergy was observed, while all combinations of trametinib and prednisolone resulted in strong to 
very strong synergy in KOPN8 (blue).
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olone. However, MEK inhibitor exposure did not alter GR protein levels in either 
SEM or KOPN8 cells (Sup.Fig.7K). 
 
Discussion
MLL-rearranged ALL in infants is a high-risk hematologic malignancy, character-
ized by a high incidence of relapse and high mortality rate.82 Recently, we showed 
that 14-24% of these patients carry a RAS mutation, as an independent predictor 
of extremely poor outcome.21 In the present study, we demonstrate that the MEK 
inhibitors trametinib, selumetinib and MEK162 display strong anti-leukemic effects 
against RAS-mutant MLL-rearranged ALL cells. Considering the dismal prognosis 
for infants suffering from MLL-rearranged ALL with additional RAS mutations, our 
data supports application of these inhibitors in the treatment of this patient group. 
Recently, Irving et al. already showed that selumetinib effectively inhibits leuke-
mia progression in an in vivo model of RAS-mutant BCP-ALL, and Burgess et al. 
found trametinib to prolong the survival of mice transplanted with NRASG12D AML 
cells.83,84 Moreover, trametinib has recently been approved for the treatment of adult 
BRAF-mutated melanoma, while different clinical trials show promising results in 
adult patients with RAS/RAF mutation positive melanoma and non-small-cell lung 
cancer for selumetinib and MEK162.85-89 Even though most clinical trials focused 
on solid tumors in adult patients, pediatric clinical trials are underway for neurofi-
bromas and gliomas, and could expedite clinical application of these MEK inhib-
itors in MLL-rearranged infant ALL. Interestingly, while all RAS-mutant MLL-re-
arranged ALL patient samples are susceptible to MEK inhibition, patients without 
RAS mutations also might benefit from MEK inhibitor treatment, since a subgroup 
of RAS-wildtype patient samples appears sensitive to MEK inhibition. While in our 
previous study, we identified RAS mutations and found no BRAF aberrations, muta-
tions of other upstream regulators, i.e. tyrosine kinase receptors, can occur in other 
malignancies.21 Andersson et al. recently showed that additional somatic mutations 
in MLL-rearranged infant ALL, like (sub-)clonal RAS/PI3K pathway aberrations, 
occur in up to 50% of the cases, supporting our previous observation that RAS muta-
tions in MLL-rearranged infant ALL frequently occur at a sub-clonal level.20,21 These 
findings do not support the hypothesis that other (upstream) mutations are driving 
RAS-MEK-ERK signaling, but also do not explain observed extensive MEK inhib-
itor sensitivity of all (subclonal) RAS-mutant and specified RAS-wildtype patient 
samples. While we found enhanced RAS and MEK activation in RAS-mutant sam-
ples, these biomarkers could not differentiate MEK inhibitor sensitive and resistant 
RAS-wildtype samples. Interestingly, Kampen et al. recently proposed a MEK inhib-
itor escape mechanism in MLL-rearranged AML, which was mediated by VEGFR-2 
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and PI3K-signaling, and we wondered whether this could play a role in the MEK 
inhibitor resistance of our wildtype patient cells.76 However, we observed no differ-
ence in downstream PI3K-signalling (i.e. Akt or p70S6 phosphorylation) in response 
to MEK inhibitor exposure. Additionally, we discovered no significant tyrosine ki-
nase receptor expression differences in MLL-rearranged infant ALL patient samples 
that could explain the MEK inhibitor response of RAS-wildtype samples. Surpris-
ingly, FGFR-1 expression was lower in MEK inhibitor resistant samples, but it is 
unclear how this would explain MEK inhibitor resistance. Alternatively, Minjgee et 
al. report that RAS-mutant transfected cells can induce downstream RAS signaling 
in a paracrine manner, through excretion of cytokines.90 Interestingly, Nakanishi et 
al. previously demonstrated that MLL-fusion proteins can induce ERK phosphoryla-
tion through regulating EphA7 receptor tyrosine kinase expression, but this was not 
accompanied by increased RAF or MEK phosphorylation.91 Still, their data shows 
that leukemic cells carrying the t(4;11) translocation are sensitive to small molecule 
inhibitors of ERK phosphorylation. These findings indicate alternative regulatory 
mechanisms for ERK signaling in MLL-rearranged leukemia could explain the MEK 
inhibitor sensitivity we observe in RAS-wildtype cells. 
Loss of ERK phosphorylation in response to MEK162, selumetinib or trametinib 
exposure confirmed the effect of MEK inhibition. Interestingly, prolonged exposure 
of cells to MEK162 or selumetinib resulted in increased MEK phosphorylation. Pre-
viously, Hatzivassiliou et al. showed that the aromatic fluorine of allosteric MEK 
inhibitor GDC-0973 interacts with MEK residue S212.92 Their data indicate this in-
teraction results in exposure of the phosphorylation sites S218/S222, which are then 
susceptible to RAF mediated phosphorylation. Since MEK162 and selumetinib both 
have this aromatic fluorine, the mechanism of interaction with MEK is probably 
similar to GDC-0973. Hence, although MEK activation in presence of GDC-0973, 
MEK162 or selumetinib can still occur, the transduction of the signal by MEK-me-
diated phosphorylation of ERK is no longer possible, as we show in Figure 4.
Recently, we found the presence of RAS mutations in MLL-rearranged infant ALL 
cells correlated with prednisolone resistance, an obstacle in the treatment of infant 
ALL.4,21 Remarkably, our present data shows that MEK inhibition strongly enhances 
the sensitivity of both RAS-wildtype and RAS-mutant MLL-rearranged ALL cells to 
prednisolone, also further exemplifying the possible value of MEK inhibitors for 
RAS-mutant, as well as RAS-wildtype, MLL-rearranged infant ALL patients. The 
prednisolone-sensitizing effect of MEK inhibitors proposes a possible role for RAS-
MEK-ERK signaling in the response to glucocorticoids. Recent work by Jones et al. 
shows that MEK plays a key role in drug resistance in relapsed pediatric ALL, and 
that MEK inhibition can sensitize ALL relapse samples to chemotherapeutics, in-
cluding methylprednisolone.93 Moreover, Ariës et al. found trametinib could restore 
prednisolone sensitivity in RAS-mutant BCP-ALL patient samples, whereas Rambal 
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et al. showed that MEK activation reduces dexamethasone sensitivity, and the MEK 
inhibitor PD183452 enhanced dexamethasone responses in ALL cells in a BIM-de-
pendent manner. 94,95 Activated ERK can phosphorylate BIM, targeting it for protea-
somal degradation, and thereby diminishing apoptosis induced by dexamethasone.96 
Moreover, we established that, while glucocorticoid receptor expression remains 
constant, MEK inhibition upregulates pro-apoptotic BIM, which implies that inhib-
iting MEK, resulting in abrogation of ERK phosphorylation, may result in prolonged 
maintenance of pro-apoptotic BIM activity upon prednisolone exposure, leading to 
enhanced prednisolone sensitivity. This is further supported by our previous study 
showing that in MLL-rearranged ALL, prednisolone sensitization mediated by pan-
BCL-2 family inhibitors was largely driven by the upregulation of pro-apoptotic 
BID and BIM.97
In summary, our data shows that RAS-mutant MLL-rearranged infant ALL patients 
may benefit from therapeutic strategies administering small-molecule MEK inhib-
itors. Furthermore, since MEK inhibition sensitizes MLL-rearranged ALL cells to 
prednisolone regardless of the RAS mutations status, RAS-wildtype MLL-rearranged 
infant ALL patients may also benefit from MEK inhibitor treatment through en-
hanced sensitivity to prednisolone. 
Acknowledgements
The authors would like to thank the members and participating institutes of the IN-
TERFANT-99 study for generously providing leukemic samples. 
Members of the INTERFANT-99 study are as follows: M. Campbell (Programa In-
fantil Nacional de Drogas Atineoplasicas (PINDA)), M. Felice (Argentina), A. Fer-
ster (Children’s Leukemia Group (CLCG)), I. Hann and A.Vora (UK Children’s Can-
cer Study Group (UKCCSG)), L. Hovi (Nordic Society of Paediatric Haematology 
and Oncology (NOPHO)), G. Janka-Schaub (Cooperative Study Group for Treat-
ment of ALL (COALL)), C.K. Li (Hong Kong), G. Mann (Berlin-Frankfurt-Munster 
Group-Austria (BFM-A)), T. LeBlanc (French ALL Group (FRALLE)), R. Pieters 
(Dutch Childhood Oncology Group (DCOG)), G. de Rossi and A. Biondi (Asso-
ciazione Italiana Ematologia Oncologia Pediatrica (AIEOP)), J. Rubnitz (St Jude 
Children’s Research Hospital (SJCRH)), M. Schrappe (Berlin-Frankfurt-Munster 
Group-Germany (BFM-G)), L. Silverman (Dana-Farber Cancer Institute (DFCI)), 
J.Stary (Czech Paediatric Haematology (CPH)), R. Suppiah (Australian and New 
Zealand Children’s Haematology/Oncology Group (ANZCHOG)), T. Szczepanski 
(Polish Paediatric Leukemia and Lymphoma Study Group (PPLLSG)), and M. Val-
secchi and P. de Lorenzo (Trial Operating Center (CORS)). 
We thank P. Garrido Castro and D. Geerts for scientific input and reading the man-
uscript.  
57
MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant ALL patients 



















































































Supplemental Figure 1. 
MTT assays of patient de-
rived RAS-mutant (solid 
line, n=6) and RAS-wild-
type (dashed line, n=14) 
t(4;11)+ infant ALL cells 
exposed to sorafenib, 
salirasib, temsirolimus 
and vemurafenib. Data 
is presented as median 
+/- sd. *0.01<p<0.05; 

























Supplemental Figure 2. (A) Western blots of MEK inhibitor resistant (Res) and sensitive (Sens) 
RAS-wildtype and RAS-mutant t(4;11)+ patient samples (left) and the matched diagnosis/relapse (Dx/
Rel) samples (right) for phosphorylated MEK (upper), total MEK (middle) and β-actin (lower). (B) 






















































































































































































































































































































































































































Supplemental Figure 3. Tyrosine kinase receptor mRNA expression (Affymetrix HU133plus2.0 
microarray data) for FLT3, VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1, FGFR-2, FGFR-3, FGFR-4, 
EGFR, ERBB2, ERBB3, ERBB4, PDGFR-A, PDGFR-B, Lck and Src in MEK inhibitor resistant 
RAS-wildtype (WT RES), MEK inhibitor sensitive RAS-wildtype (WT SENS) and RAS-mutant (MUT) 
primary samples.
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Supplemental Figure 4. (A) Western blots of SEM (two upper panels) and KOPN8 (two lower panels), 
exposed for 6, 24 and 48 hours to either vehicle (DMSO) or selumetinib, MEK162 or trametinib, detect-
ing phosphorylated ELK-1 and total ELK-1. (B) Western blots of SEM and KOPN8, exposed to afore-
mentioned MEK inhibitor conditions, for phosphorylated and total Akt. (C) Western blots of SEM and 
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Supplemental Figure 5. Western blots of 
SEM and KOPN8 exposed for 48 hours to 
DMSO (D), selumetinib (S), MEK162 (M) or 
trametinib (T), for determination of BIM and 
p53 protein levels. Actin was used as loading 
control.
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Supplemental Figure 6. Representative graphs of percentages SEM (A,C,E) or KOPN8 (B,D,F) 
cells in G2/M (white), S (grey) or G0/G1 (black) cell cycle stages, as analyzed by DNA staining. Cells 
were exposed to vehicle control (DMSO) or 500 nM MEK162, selumetinib or trametinib for 24, 48 or 
72 hours (A and B, C and D, E and F, respectively).
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Supplemental Figure 7. (A) Dose-response curves of the SEM cell line exposed to prednisolone alone 
(black curve) or in combination with 3.125 μM, 6.25 μM, 12.5 μM or 25 μM MEK162 (red, blue, 
green and grey curves, respectively). Low concentrations of MEK162 sensitize cells towards pred-
nisolone. (B) Response of SEM to the single MEK162 concentrations used in A. (C) Dose-response 
curves of KOPN8 treated with prednisolone (black curve), or in combination with the aforementioned 
MEK162 concentrations (shown in red, blue, green and grey, respectively). KOPN8 cells are also sensi-
tized towards prednisolone by co-exposure with low concentrations of MEK162. (D) KOPN8 exposed 
to single MEK162 concentrations. (E) Dose-response curves of the SEM cell line exposed to either 
prednisolone alone (black), or in combination with selumetinib (at the same concentrations used for 
MEK162). Low concentrations of selumetinib can sensitize SEM cell towards prednisolone. (F) Effect 
of different single selumetinib concentrations in SEM. (G) Combined exposure to prednisolone and low 
selumetinib concentrations also sensitizes KOPN8 cells. (H) Response of KOPN8 towards single con-
centrations of selumetinib. (I) Combined exposure to prednisolone and MEK162 (n=3) was quantified 
using FSyn calculations (FSyn<1 indicates synergy) and plotted against fractional effect (i.e. inhibition 
of cell viability). In both SEM (red) and KOPN8 (blue), moderate to strong synergy was observed. (J) 
Combinatorial effect of prednisolone and selumetinib co-exposure (n=3) was quantified using FSyn 
calculations. Moderate to strong synergistic effects between prednisolone and selumetinib are observed 
for both SEM (red) and KOPN8 (blue). (K) Western blots of SEM and KOPN8 exposed for 48 hours 
to DMSO (D), selumetinib (S), MEK162 (M) or trametinib (T), detecting glucocorticoid receptor (GR) 
and loading control (Actin).
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Trametinib inhibits RAS-mutant MLL-rearranged acute 
lymphoblastic leukemia at specific niche sites and 
reduces ERK phosphorylation in vivo
Mark J.B. Kerstjens, Sandra Mimoso Pinhanços, Patricia 
Garrido Castro, Pauline Schneider, Priscilla Wander, Rob Pieters 





The majority (~80%) of infant ALL cases is characterized by chromosomal rear-
rangements involving the Mixed Lineage Leukemia (MLL, or KMT2A) gene, which 
confer a poor prognosis: event-free survival chances are at best 30-40%.4 We and 
others showed (sub-clonal) RAS mutations occur in 14-36% of MLL-rearranged ALL 
cases, depending on MLL-translocation subtype.20-22 RAS mutations diminish surviv-
al chances even further, with rapid occurrence of relapses and essentially no chance 
of survival.21 Recently, we found that MEK inhibitors effectively killed RAS-mutant 
infant ALL cells in vitro, with trametinib being the most potent compound tested.98 
We therefore proposed that trametinib could be beneficial for MLL-rearranged infant 
ALL patients harboring additional RAS mutations. Here, we report preclinical eval-
uation of trametinib in a RAS-mutant MLL-rearranged infant ALL mouse xenograft 
model. 
Since trametinib was previously investigated in mouse models for other malignan-
cies and was accepted for treatment of BRAF-mutant melanoma,99,100 we based our 
dosing regime on these studies, administering 5 mg/kg (low) or 30 mg/kg (high) 
trametinib 3 times per week through intraperitoneal injection in a toxicity assess-
ment (n=3 mice per group). Within a week 2/3 mice in the 30 mg/kg trametinib 
group died, while the final mouse was humanely euthanized due to weight loss. The 
vehicle and 5 mg/kg trametinib doses were tolerable for up to 28 days, without signs 
of discomfort or weight loss (Sup.Fig.1A). One of the trametinib mice was smaller 
than its littermates, but there were no indications to exclude it from the study. He-
matoxylin and eosin (H&E) staining of tissue slices revealed that high trametinib 
dosing induced kidney damage, which was absent in the vehicle and low trametinib 
groups (Sup.Fig.1B). Surprisingly, high dose trametinib also resulted in enhanced 
abundance of myeloid cells in the spleen (Sup.Fig.1C), which resembled splenic 
extramedullary hematopoiesis (EMH).101 Moreover, we observed hematopoietic cell 
depletion in bone marrows of mice that received low trametinib doses, while this did 
not occur in the vehicle treated mice (Sup.Fig.1D). Although bone marrow tissue for 
high dose trametinib was unavailable, possibly high dose trametinib induces more 
severe bone marrow depletion, evoking splenic EMH. 
To assess the efficacy of trametinib in vivo, we transplanted NSG mice with the 
RAS-mutant MLL-rearranged infant ALL cell line KOPN8 (106 cells; tail-vein in-
jection), previously transduced with a luciferase-reporter (from here on referred to 
as KOPN8-SLIEW). After 1 week engraftment was assessed through intra-vital im-
aging. After randomization, vehicle or trametinib treatment (5 mg/kg, three times 
per week) commenced and leukemia progression was tracked by weekly intra-vital 
imaging. In both the vehicle and trametinib treated mice, systemic leukemia devel-
oped over a period of 2 weeks, although more severely in the vehicle mice, most 
evidently on day 14 (Fig.1A, left). Quantification of the intra-vital imaging revealed 
trametinib monotherapy delayed leukemia progression, but was insufficient to pre-
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vent leukemia outgrowth (Fig.1B). The modest effect of trametinib on leukemia pro-
gression led us to investigate whether its mechanism of action was achieved at all 
in our model. Therefore, 4 hours before sacrificing the mice (day 17), 2 mice from 
the vehicle group and 2 mice from the trametinib group were randomly selected to 
receive a bolus injection of trametinib (5 mg/kg) for analysis of ERK activation in 
tissue samples later on. Spleen, bone marrow and peripheral blood samples were 
extracted from all mice. As expected from the intra-vital imaging data, both treat-






































































































































Figure 1. RAS-mutant MLL-rearranged leu-
kemia progression is tempered by trametinib. 
(A) Intra-vital imaging of KOPN8-SLIEW 
transplanted mice receiving either vehicle or 
trametinib treatment. Images were acquired on 
day 7 (top) and day 14 (bottom), and presented 
using the same luminescent scale. (B) Quantifi-
cation of intra-vital imaging data of each indi-
vidual mouse from the vehicle and trametinib 
groups (red and blue, respectively), as measured 
on day 0 (pre-treatment), day 7 and day 14. Data 
are presented as photonic flux (i.e. the number 
of emitted photons per second). (C) Spleen weights of vehicle and trametinib mice. (D,E,F) Percent-
ages of leukemic (huCD19+/msCd45-/Ter119-) cells detected in spleen, bone marrow and peripheral 
blood, respectively. The data from mice that received a trametinib bolus are indicated as blue dots.
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weight (Fig.1C; Sup.Fig.2A). After processing the tissues, the presence of leukemic 
cells was analyzed using flow cytometry (example gating shown in Sup.Fig.2B).   
The majority of cells derived from either vehicle or trametinib treated spleens repre-
sented human leukemia cells (Fig.1D). However, the leukemic load in bone marrow 
aspirates was reduced to 10-30% in 4 out of 8 trametinib treated mice, while the 
remaining mice presented with leukemic bone marrows similar to the vehicle treated 
group (80-95%) (Fig.1E). Additionally, we observed a reduction of leukemic cells 
in the peripheral blood of trametinib treated mice compared to vehicle (12% and 
23%, respectively), although this difference was not statistically significant (Fig.1F). 
The mice that received a trametinib bolus-injection (blue dots) were comparable to 
the non-bolus mice. The bimodal effect observed in bone marrow aspirates did not 
correlate with gender, total or spleen weight, leukemic cells in the peripheral blood 
or age (Sup.Fig.2C).
To further investigate leukemic cell distribution in the bone marrows of trametinib 
and vehicle treated mice, we performed H&E staining on bone marrow tissue slices. 
Interestingly, in the vehicle bone marrows we observed severe leukemic cell infil-
tration, whereas the selected bone marrows of trametinib treated mice, with reduced 
leukemic load, actually showed hypocellularity (Fig.2A). Although these hypocel-
lular bone marrows differ from healthy bone marrow, this is likely due to trame-
tinib-induced leukemic cell death rather than toxicity, as the approval of trametinib 
for metastatic melanoma and recent clinical studies in other haematologic diseases 
suggest.102  
Since RAS mutations in MLL-rearranged infant ALL have been implicated with en-
hanced central nervous system (CNS) infiltration,103 we investigated fixated skull 
sections for presence of leukemic cells. Interestingly, trametinib substantially re-
duced leukemia infiltration into the leptomeningeal space in 2 out of 3 trametinib 
treated mice, whereas all vehicle mice presented with cell invasion (Fig.2B). 
We electrophoretically resolved protein lysates of spleen and bone marrow samples 
and investigated ERK dephosphorylation as marker for trametinib efficacy. Interest-
ingly, vehicle non-bolus spleen samples had evident ERK phosphorylation (pERK), 
while the vehicle mice that received a bolus presented with markedly lower pERK 
signal (Fig.2C). Moreover, trametinib inhibited ERK phosphorylation in all spleen 
isolates, both by successive trametinib injections (black bars), as well as a single bo-
lus injection in vehicle group mice (white bars), as was confirmed by quantifying the 
relative pERK signal of these blots (Fig.2E). Additionally, the bone marrow samples 
of bolus and non-bolus mice (before purification by magnetic-activated cell sorting: 
MACS) contained comparable percentages of leukemic cells (Sup.Fig.3A). Inter-
estingly, the vehicle bone marrow samples showed a similar ERK phosphorylation 
pattern as the spleen samples, with the trametinib bolus lowering the pERK level 
(Fig.2D), while in the trametinib group, the bolus injection was also accompanied 
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Figure 2. Trametinib impinges on niche 
distribution of RAS-mutant MLL-re-
arranged ALL cells and reduces ERK 
phosphorylation in vivo. (A) H&E 
stained bone marrow slides from 2 vehi-
cle (top) and 2 trametinib (bottom) treat-
ed mice. (B) H&E stained slices from the 
skull of 3 vehicle (top) and 3 trametinib 
(bottom) treated mice. (C) pERK and total 
ERK levels were analyzed by western blot 
in MACS-enriched spleen isolates from vehicle or trametinib mice. Bolus trametinib injection sam-
ples are indicated by ‘+’. (D) pERK and total ERK levels determined by western blot of MACS-en-
riched bone marrow aspirates. Samples from mice that received a bolus trametinib injection are indi-
cated by ‘+’. (E,F) The pERK/total ERK ratio as quantified from the western blots shown in C and D, 
respectively. Quantification data are presented as mean +/- sd.
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by reduced ERK phosphorylation. Quantifying the blots revealed that in non-bolus 
bone marrows there was little difference between the vehicle and trametinib groups, 
though a bolus of trametinib effectively diminished ERK phosphorylation (Fig.2F). 
Hence, successive trametinib treatment did not result in maintained pERK reduc-
tion, as observed in the spleen, but bolus trametinib injections transiently decreased 
pERK levels in the bone marrow. 
Although MEK inhibition previously proved effective in a RAS-mutant BCP-ALL 
xenograft model, trametinib could not substantially inhibit leukemia progression 
in our MLL-rearranged infant ALL model.83 However, trametinib treatment did im-
pinge on engraftment localization, specifically bone marrow and brain infiltration of 
RAS-mutant MLL-rearranged ALL cells. The difference in efficacy of MEK inhibi-
tion between RAS-mutant MLL-rearranged ALL and BCP-ALL might be explained 
by differences in cytogenetic subtype and associated outcome. 
Interestingly, Prieto et al. showed that in mouse xenografts of human MLL-rear-
ranged ALL cell line SEM, ectopic expression of KRASG12V significantly promoted 
CNS infiltration, which together with our data suggests MEK inhibition might di-
minish CNS involvement.103 Furthermore, MEK inhibitor selumetinib significantly 
reduced CNS infiltration in a pediatric RAS-mutant BCP-ALL xenograft model.83 
Spleen-derived leukemic cells from the trametinib group showed sustained reduced 
pERK levels, whereas a bolus trametinib injection could also reduce pERK in the 
vehicle group. Furthermore, we observed bone marrow hypocellularity in 4 out of 8 
mice after trametinib treatment, while ERK phosphorylation was reduced after a tra-
metinib bolus in the mice with highly leukemic bone marrows. Possibly trametinib 
clearance reduces its effect or alternate signaling mechanisms restore pERK, and our 
dosing frequency is too low to induce sustained inhibition of ERK phosphorylation. 
Although more frequent dosing might improve efficacy, there is a risk for toxicity. 
However, other studies in patient-derived solid tumor xenografts have used daily 
oral dosing regimes (0.3 to 3 mg/kg), and while we chose intraperitoneal adminis-
tration to better control trametinib levels, these protracted studies for some models 
resulted in better efficacy than we observed.
Survival chances for MLL-rearranged infant ALL patients carrying RAS mutations 
are close to zero.21 Since trametinib reduces ERK phosphorylation, a key down-
stream effect of mutant RAS, this implies that trametinib treatment could revert the 
effect of RAS mutations in MLL-rearranged ALL, inducing a response to standard 
therapy that more resembles RAS-wildtype MLL-rearranged ALL. Moreover, glu-
cocorticoid resistance remains a detrimental feature of MLL-rearranged infant ALL, 
and is associated with RAS mutations.4,21,27,104 Previously, we and others have shown 
that MEK inhibitors trametinib, selumetinib and MEK162 could sensitize ALL to 
glucocorticoids.95,98,105 This suggests that combination therapy of trametinib with 
glucocorticoids could be beneficial.
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In conclusion, though trametinib monotherapy was unable to systemically inhibit 
RAS-mutant MLL-rearranged ALL in vivo, bone marrow leukemic burden was re-
duced in half of the mice, and trametinib effectively reduced ERK phosphorylation 
in leukemic cells from bone marrows and spleens. This illustrates the potential value 
of MEK inhibitors through reduction of CNS infiltration and possible potentiation of 
glucocorticoid sensitivity.
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Animal experiments were performed in accordance with Dutch legislation and ap-
proved by the Erasmus MC Animal Ethical Committee, Rotterdam, The Netherlands 
(EMC3389). Immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice 
from in-house breeding received a tail-vein injection with the previously generated 
KOPN8-SLIEW luciferase reporter cell line (106 cells/mouse). After 1 week, mice 
underwent intra-vital bio-imaging (IVIS Spectrum Imaging System, Perkin Elmer) 
after injection of luciferin (RediJect D-Luciferin Bioluminescent Substrate, Perkin 
Elmer). Subsequently, mice were assigned to the respective treatment groups, and 
received vehicle (10% DMSO in PEG300; Sigma-Aldrich) or trametinib (5 mg/kg; 
MedChemExpress) intraperitoneally 3 times per week. Leukemia progression was 
monitored through weekly intra-vital imaging until the end of the study and acquired 
images were analyzed using Living Image software (Perkin Elmer), with equal ex-
posure setting for all mice per time point.  
At the end of the study, 2 vehicle and 2 trametinib mice received a bolus injection of 
trametininb (5 mg/kg) 4 hours prior to sacrifice. All mice were humanely euthanized 
through CO
2
 asphyxiation and peripheral blood (PB) and tissues were harvested for 
further analyses. Leukemic burden in PB and infiltration into bone marrow (BM) and 
spleen were determined using a multicolor immunotyping flow cytometry approach. 







, 0.1 mM EDTA, pH 7.3-7.5). Bone marrows (tibia and femur) were 
flushed with PBS and resuspended to single cell suspension. Spleens were homog-
enized through a cell strainer (EASYstrainer, 70 µM, Greiner Bio-one), mixed with 
RBC lysis buffer and splenocytes were resuspended in PBS. Magnetic-activated cell 
sorting (MACS) was performed using anti-human CD19 magnetic particles (BD 
Biosystems). Example gating shown in Sup.Fig.3B-D.
Subsequent immunotyping flow cytometry was performed using 7-AAD, human 
CD19-APC, human CD45-PE, mouse Cd45-PE-Cy7 and mouse Ter119-PE-Cy7 
(all BD Biosystems). Samples were measured on a MACSQuant flow cytometer 
(Miltenyi) and analyzed using FlowJo software. 
Tissues were fixated in 4% formaldehyde and embedded in paraffin. Tissue slides 
were stained with hematoxylin and eosin (H&E). Images were acquired with a Leica 
digital microscope. 
Western blot
Cell lysates were electrophoretically resolved on pre-cast SDS-polyacrylamide gels 
(AnyKD, TGX, Bio-Rad, Veenendaal, The Netherlands) and transferred to nitrocel-
lulose membranes using the Transblot Turbo Transfer System (BioRad, Veenendaal, 
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The Netherlands). Membranes were blocked with 5% bovine serum albumin in TBS 
and probed with pERK or total ERK antibodies (Cell Signalling Technologies), fol-
lowed by fluorophore-conjugated secondary antibodies. Blot mages were acquired 
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Supplemental Figure 1. (A) Progressive weight measurements of NSG mice injected with vehicle 
(n=3; red) or 5 mg/kg trametinib (n=3; blue). (B) Representative H&E stained kidney sections from 
wildtype mice and vehicle, 5 mg/kg trametinib or 30 mg/kg trametinib exposed mice (from left to right, 
respectively). (C) Representative H&E stained spleen sections from wildtype mice and vehicle, 5 mg/
kg trametinib or 30 mg/kg trametinib exposed mice (from left to right, respectively). Part of the 30 mg/
kg trametinib section has been enlarged for more detail. (D) Representative H&E stained bone marrow 
slides from wildtype (left), vehicle (center) and 5 mg/kg trametinib (right) treated mice.
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Supplemental Figure 2. (A) Pictures of spleens from wildtype (left), vehicle (center) and trametinib 
(right) group mice. (B) Exemplary gating strategy for determining the percentage human CD19-pos-
itive, mouse Cd45/Ter119-negative cells. Shown are FACS plots of pure KOPN8-SLIEW (left) and a 
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homogenized spleen sample from a mouse xenograft (right). (C) Graphs showing the percentage of leu-
kemic cells in bone marrow aspirates from vehicle and trametinib treated mice as presented in Fig.1C 
(Original), as well as the same data subdivided for gender, or subdivisions of vehicle, and high and low 
leukemic bone marrows from the trametinib group for total weight, spleen weight, percentage leukemic 


















































Supplemental Figure 3. (A) Percentages of leukemic 
(huCD19+/msCd45-/Ter119-) cells in bone marrow aspirates 
of selected non-bolus (black) and bolus (gray) mice from 
Fig.1E. (B) Gating strategy for post-MACS flow-cytometry 
detection of leukemic cells in isolated mouse tissues, based on 
pure KOPN8-SLIEW sample. (C) FACS example of a spleen 
isolate before (pre-MACS; left) and after (post-MACS; right) 
enrichment, to confirm successful MACS procedure. (D) 
FACS example of a bone marrow isolate before (pre-MACS; 
left) and after (post-MACS; right) enrichment, to confirm suc-
cessful MACS procedure.
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Drug discovery and MLL-rearranged infant ALL
One of the most pressing drug development challenges in general is the high rate of 
attrition.128 This is especially true for oncology drugs in clinical trials, which over the 
time period 2003-2011 reached a mere 6,7% likelihood of approval (i.e. the percent-
age of drugs that progress from phase 1 to FDA-approval).129 Clearly, improvements 
in drug discovery and development are needed, with an emphasis on prediction of 
clinical safety profiles and efficacy. Input from studies on approved drugs, as well 
as drug failures, has played an important role in the development of predictive tools 
for classification of drug-like properties in medicinal chemistry.130,131 However, pro-
gression of novel molecular entities from discovery towards clinical application is 
slow. Moreover, for drugs to make the transition to pediatric clinical investigation, 
extensive clinical data in adults is required, further protracting the application of de 
novo therapeutics in children. Additionally, MLL-rearranged infant acute lympho-
blastic leukemia (ALL) is a rare disease that differs significantly from ALL in older 
children and adults, which further complicates clinical investigation.5 While signif-
icant advances have been made over the past decades, including the initiation of 
infant-specific treatment protocols and improved risk stratification, lifting MLL-re-
arranged infant ALL survival chances to approximately 40-50% nowadays, the bal-
ance between therapeutic efficacy and toxicity of the current chemotherapeutics is 
delicate.4,48 Hence, novel therapeutic strategies for MLL-rearranged infant ALL pa-
tients are clearly needed. Although the discovery of druggable targets and associated 
therapeutic small molecules is generally a valid approach, so far this has not led to 
improved outcome for these patients. This has led us to investigate drug repurposing 
as a tool to identify already approved therapeutics for which implementation into 
clinical trials can occur much quicker. 
Drug repurposing 
Drug repurposing has received extensive interest and has formed the basis for one of 
the research approaches in this thesis.40 As reported in chapter 2, screening of over 
3500 FDA-approved or off-patent drugs yielded a number of promising hits and 
resulted in the identification of topoisomerase I inhibitor SN-38 in vitro, and the suc-
cessful pre-clinical efficacy assessment of the SN-38 prodrug irinotecan in MLL-re-
arranged in vivo xenograft mouse models. The amount of data on clinical use of 
irinotecan against other types of cancer, in both adult and pediatric cancer patients, 
is extensive and should provide medical practitioners with important information on 
pharmacodynamics and pharmacokinetic properties, to expedite the transition to-
wards implementation in infant ALL treatment protocols. The drug repurposing ap-
proach may potentially increase accessibility and reduce costs of therapeutics, and its 
usefulness has been shown in different diseases, including vaccinia virus infection, 
multi-drug resistant tuberculosis, Parkinson’s Disease and cancer.132-135 Moreover, 
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it is particularly well suited for rare (orphan) and neglected diseases, which suffer 
from reserved interest of big pharmaceutical companies.136,137 Our data exemplify the 
value of investigating drug repurposing as an alternative to target discovery and de 
novo drug design efforts for rare and aggressive diseases. Interestingly, adaptations 
of the drug repurposing approach are also being employed as tools in drug discovery. 
For example, chemical informatics databases with information on drug structures 
and associated targets predict targets for new drugs or vice versa, as well as potential 
off-target effects, whereas profiling of drug-induced alterations in gene expression 
have aided drug discovery and repositioning.34,138-140 More recently, Legehar et al. 
have developed an approved drug database describing a plethora of parameters (i.e. 
ADMET information, molecular descriptors, targets and bioactivity) for thousands 
of small molecules and biologics.141 These and new developments are expected to 
make a significant contribution to future drug discovery in general. 
Targeted therapies for MLL-rearranged infant ALL
Our drug library screening reported in chapter 2, besides identifying SN-38/irinotec-
an as promising, though not MLL-rearranged ALL specific, therapeutic strategy, also 
indicated that in a large panel of FDA-approved drugs no MLL-rearranged infant 
ALL specific inhibitors could be identified. Considering the clinical and biological 
distinction from MLL germline infant ALL and BCP-ALL in older children, this 
implies that novel therapies against disease-specific mechanisms of MLL-rearranged 
ALL are needed.16,17,28 
In chapter 3 we investigated targeted therapeutic options for MLL-rearranged infant 
ALL patients harboring additional RAS mutations, an infant ALL subgroup (24%) 
with an extremely poor prognosis, by testing inhibitors against RAS-pathway com-
ponents.21 While we found that MEK inhibitors inhibited RAS-mutant MLL-rear-
ranged infant ALL patient cells and induced sensitization to prednisolone in vitro, 
the in vivo validation of MEK inhibitor trametinib showed limited systemic efficacy 
as monotherapy, but still managed to affect leukemic cell localization and reduce 
ERK phosphorylation (chapter 4). Although trametinib affected ERK phosphoryla-
tion in our xenograft mouse models, the dosing regime might not have been frequent 
enough to induce a sustained effect. However, more frequent dosing of trametinib is 
hampered by the toxicity we observed at higher dosages. 
Previously, inhibition of downstream RAS signaling, especially at the level of MEK/
ERK, has been shown to contribute to enhanced sensitization towards glucocorti-
coids in non-infant childhood ALL.95 Since MLL-rearranged infant ALL is notorious 
for its resistance to glucocorticoids, most evidently in RAS-mutant leukemia, MEK 
inhibition could be a valuable option for combination therapy, and further pre-clin-
ical in vivo validation is warranted. With trametinib approved for metastatic mela-
noma, and several clinical trials in progress, addition of trametinib to infant ALL 
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treatment protocols might be an option for overcoming glucocorticoid resistance. 
Since MLL-rearranged ALL is characterized by aberrant epigenetic regulation, illus-
trated by perturbed histone modifications and DNA methylation patterns resulting 
in a distinct gene expression profile, it is no surprise that therapeutic strategies im-
pinging on epigenetic modifiers (both “writers” and “readers”) have been the core 
subject of targeted drug discovery research. In chapter 5 we screened two small 
epigenetic drug libraries for inhibitors of MLL-rearranged ALL cells. Amongst the 
most effective compounds we found histone deacetylase (HDAC) inhibitors, as well 
as S-adenosylhomocysteine hydrolase (SAHH) inhibitors. The mechanism of action 
for the latter was particularly intriguing, since SAHH plays a key role in replenishing 
the methyl donor S-adenosylmethionine (SAM).115 Although we showed SAHH in-
hibitor DZNep killed leukemic cells (but not healthy bone marrow) in vitro, this was 
not MLL-rearanged ALL specific, as BCP-ALL cells with other translocations were 
affected to a comparable extent. Furthermore, while we observed increased SAH 
and reduced SAM levels, this did not drastically influence methylation, and although 
DZNep reduced splenic infiltration in vivo in xenograft mouse models of MLL-rear-
ranged ALL, no difference in systemic leukemia was detected. Since DZNep, added 
to combination chemotherapy, showed enhanced anticancer effects in other malig-
nacies, further investigation into synergistic (epigenetic) drug combinations might 
be promising.107,124 In fact, several other epigenetic drug candidates, like azacytidine, 
are currently under investigation in MLL-rearranged infant ALL. 
Epigenetic therapies in development
Although there is ambiguity about which specific HDAC isoforms are essential in 
ALL, different preclinical studies have reported promising results for HDAC inhib-
itors, and MLL-rearranged infant ALL cell lines and patient samples are particularly 
sensitive towards HDAC inhibition.34,142 Moreover, as we recently showed, HDAC 
inhibitor panobinostat effectively impedes MLL-rearranged infant ALL progression 
in xenograft mouse models of both cell line and patient-derived MLL-rearranged 
infant ALL cells.35 Furthermore, our study also suggests inhibition of an H2B ubiq-
uitin ligase complex as key in the mechanism of action of panobinostat in MLL-re-
arranged infant ALL. The recent approval of panobinostat for multiple myeloma in 
adults will hopefully expedite transition towards clinical investigation for pediatric 
malignancies as well.143 
Additionally, due to promoter hypermethylation in MLL-rearranged ALL, demeth-
ylating agents have been investigated extensively, with nucleoside analogues decit-
abine, 5-azacytidine and clofarabine as most promising compounds.16 Interestingly, 
the first two drugs have been FDA-approved for myeloid malignancies in adults, 
which might expedite transition towards clinical application in pediatric cancer.144 
Moreover, clinical trials for 5-azacytidine as addition to current MLL-rearranged 
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infant ALL treatment protocols are underway, while clofarabine will be investigated 
for infant patients.
The histone methyltransferase DOT1L is pivotal to MLL-rearranged ALL mainte-
nance and can be targeted by a small molecule inhibitor (EPZ-5676).32 Furthermore, 
EPZ-5676 is under phase 1 clinical investigation for MLL-rearranged leukemia in 
adults, as well as pediatric patients. Recently, a study on two MLL-rearranged AML 
cell lines showed synergistic enhancement of anti-leukemic effects for EPZ-5676 in 
combination with standard AML therapies, as well as a number of epigenetic ther-
apeutics.145 With limited in vivo data on DOT1L inhibitors in MLL-rearranged ALL 
models, and MLL-rearranged ALL cell lines being less sensitive to EPZ-5676 than 
AML cells, it is currently unclear whether DOT1L inhibitors could be beneficial for 
MLL-rearranged infant ALL.  
Another interesting class of epigenetic inhibitors targets the BET protein family (i.e. 
BRD2-4 and BRDT), which mediates formation of MLL fusion protein complexes 
that drive transcription.37 Recently, we found I-BET151 deregulates BRD4 chroma-
tin recruitment and effectively impedes primary MLL-rearranged ALL progression 
in vivo.146 Other BET inhibitors are under clinical investigation for different solid 
and hematologic cancers in adults.
Conclusion
Through drug repurposing we identified SN-38 and irinotecan as possible effective 
drugs for MLL-rearranged infant ALL. The future of targeted therapies for MLL-re-
arranged infant ALL lies with the further development of novel epigenetic drugs and 
disruption of interactions within MLL-associated protein complexes, such as recent-
ly reported MLL-Menin inhibitors.56,147 The progression of these promising thera-
peutics in (pre)clinical trials, especially the investigation of epigenetic combination 
treatment protocols, is of great interest and hopefully will have a positive impact on 
the treatment of MLL-rearranged infant ALL in the near future. 
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Ons lichaam bestaat uit meer dan 30 triljoen (30.000.000.000.000) cellen, die samen-
werken om ons gezond te houden. Om de verschillende celtypes in ons lichaam te 
laten functioneren, hebben wij ongeveer 5 liter bloed, met ook weer verschillende 
soorten cellen met elk hun eigen belangrijke taak. Zo bestaat ons bloed uit cellen die 
zuurstof en koolstofdioxide transporteren (rode bloedcellen), cellen die zorgen dat 
bloed stolt bij een wondje (bloedplaatjes), en cellen die bescherming bieden tegen 
ziekteverwekkers (witte bloedcellen). Al deze verschillende bloedcellen stammen 
af van één voorloper cel, ook wel bloedstamcel genoemd. Dit type stamcel heeft 
her vermogen om zichzelf zeer vaak te vermenigvuldigen, en kan zich ook via ver-
scheidene stappen verder ontwikkelen (rijpen) en zo veranderen in de verschillen-
de bloedcellen. Dit wordt ook wel differentiëren genoemd. Tijdens de embryonale 
ontwikkeling vindt de productie van bloedcellen voornamelijk plaats in de lever, tot 
ongeveer 2 maanden voor de geboorte, wanneer het beenmerg de belangrijkste plek 
van de bloedaanmaak wordt. 
Leukemie 
Wanneer onrijpe witte bloedcellen (die nog niet functioneel zijn) ongeremd gaan 
delen, ontstaat er leukemie, ook wel bloedkanker genoemd. De voortgang van leu-
kemie kan snel en agressief zijn, wat ook wel acute leukemie genoemd wordt. Aan 
de andere kant kan de deling en verspreiding van de cellen langgerekt zijn, wanneer 
er sprake is van chronische leukemie. Naarmate de leukemie zich verder ontwikkelt, 
verdringen de onrijpe witte bloedcellen de gezonde bloedcellen, wat ervoor zorgt 
dat de aanmaak van rode bloedcellen, bloedplaatjes en gezonde witte bloedcellen 
geblokkeerd wordt. Dit belemmert zuurstof/koolstof dioxide transport, bloedstolling 
en het afweersysteem. Binnen acute leukemie, wordt er onderscheid gemaakt aan de 
hand van de voorloper cel waar de leukemie uit ontstaan is. Zo kan er sprake zijn van 
acute myeloïde leukemie (AML) of acute lymfatische leukemie (ALL). Kinderen 
met leukemie hebben in de meeste gevallen acute lymfatische leukemie, waarvan in 
Nederland ongeveer 125 nieuwe gevallen per jaar worden vastgesteld. De afgelopen 
decennia is de behandeling van ALL bij kinderen sterk verbeterd. Dit komt onder an-
dere door het gebruik van chemotherapie, meer kennis over deze ziekte en het beter 
kunnen identificeren van risicofactoren voor een slechte prognose. Hierdoor is de 
overlevingskans van kinderen met ALL van minder dan 10% in de jaren ’60 inmid-
dels gestegen tot ongeveer 90% overleving. Helaas hebben deze ontwikkelingen niet 
voor alle kinderen met ALL tot zo’n geweldige verbetering geleid, in het bijzonder 
niet voor de allerjongste patiëntjes, namelijk de zuigelingen (kinderen jonger dan 1 
jaar).  
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MLL-herschikte acute lymfatische leukemie bij zuigelingen
In Nederland wordt jaarlijks bij 5 zuigelingen acute lymfatische leukemie gediag-
nostiseerd. De meerderheid van deze baby’s (~80%) heeft een specifiek defect in het 
DNA. Van de 46 chromosomen in een cel, zijn er in dit geval 2 gebroken en verkeerd 
weer aan elkaar gelijmd, precies op een stuk dat codeert voor het MLL gen. Hierdoor 
is een stuk van het MLL gen aan een ander gen geplakt, wat ook wel een MLL-her-
schikking wordt genoemd. Bij de zuigelingen die géén MLL-herschikking hebben 
(~20% van de zuigelingen met ALL) is de overleving op de lange termijn ~75%, dus 
redelijk in de buurt van de overleving bij oudere kinderen met ALL. Maar zuigelin-
gen met een MLL-herschikking hebben een veel slechtere prognose, met ongeveer 
50% kans op overleving. 
Het “gezonde” MLL gen wordt in de cel omgezet naar het MLL eiwit, dat betrokken 
is bij het reguleren van de bloedaanmaak. Normaalgesproken zijn er in (bloed voor-
loper) cellen verschillende signalen nodig om de cel bijvoorbeeld te laten delen of te 
differentiëren. Dat betekent dat de werking van het MLL eiwit onder controle staat 
van weer andere signalen en eiwitten. Maar in cellen met een MLL-herschikking 
worden er eiwitten aangemaakt die voor de helft uit MLL bestaan, en voor de andere 
helft uit een ander eiwit. Deze fusie-eiwitten kunnen nog wel allerlei processen in de 
cel aan- of uitzetten, maar zijn niet meer gevoelig voor de strenge controle die er in 
de cel is. Zo treden er in de leukemie cellen veranderingen op die MLL-herschikte 
ALL onderscheiden van ALL bij zuigelingen zonder MLL-herschikking en ALL bij 
oudere kinderen. 
Hoewel de MLL-herschikking vaak de drijvende factor is bij ALL in zuigelingen, 
is er ook onderzoek gedaan andere fouten in het DNA die bijdragen aan de slechte 
prognose. Zo is er recent vastgesteld dat bij sommige patiënten een deel van de leu-
kemiecellen een mutatie heeft in het RAS gen. Deze mutatie wordt geassocieerd met 
resistentie tegen chemotherapie en dus een nog slechtere prognose. 
Ziektebeeld en huidige therapieën
Bij MLL-herschikte ALL zijn de leukemie cellen te herkennen als zeer onrijp, wat 
betekent dat ze nog dicht tegen het voorloper cel stadium aan zitten en dus nauwe- 
lijks gedifferentieerd zijn. Naast onrijpe witte bloedcellen, zijn er een aantal klinische 
kenmerken die MLL-herschikte leukemie karakteriseren en een indicator zijn voor 
een slechte prognose, waaronder leeftijd bij diagnose (<6 maanden), hoog aantal 
witte bloedcellen, beperkte effectiviteit van chemotherapie (prednison) gedurende 
de eerste week behandeling en infiltratie van leukemiecellen in het centraal zenuw- 
stelsel. Hoewel het merendeel (~85%) van zuigelingen met MLL-herschikte ALL in 
eerste instantie goed reageert op de behandeling, komt de leukemie bij twee derde 
van de patiënten terug (ook wel relapse genoemd), resulterend in slechts 50% kans 
op overleving. Het huidige behandelingsprotocol wordt internationaal toegepast, en 
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bestaat uit een 2-jarige behandeling met verschillende chemotherapeutica, met onder 
andere glucocorticoïden (prednison, dexamethason), antimetabolieten (cytarabine, 
methotrexaat), asparaginase, daunorubicine en vincristine. Daarnaast komen patiënt-
en die wel goed reageren op therapie in aanmerking voor stamcel transplantatie. 
Helaas is intensiever behandelen van patiënten niet mogelijk, omdat dit zou resul-
teren in verhoogde toxiciteit en behandeling-gerelateerde sterfte. Gezien het hoge 
aantal relapsen bij MLL-herschikte leukemie bij zuigelingen, moeten we conclu- 
deren dat de huidige behandeling niet genoeg is voor genezing. Daarom focust het 
recente onderzoek naar behandelmethodes voor deze ziekte zich op de ontwikkeling 
van nieuwe en meer doelgerichte medicijnen.  
Medicijnontwikkeling in een notendop
Bij de ontwikkeling van nieuwe medicijnen, richt het onderzoek zich in eerste in-
stantie op het begrijpen van het ziektebeeld en waardoor dit veroorzaakt wordt. Vaak 
is er een fout in het DNA, wat resulteert in de aanmaak van een eiwit wat niet meer 
werkt, of juist te actief is. De volgende stap is het vinden van een chemische struc- 
tuur die in staat is om de werking van het eiwit te repareren. De chemische stof zal 
met het eiwit een specifieke interactie moeten aangaan, oftewel: aan het eiwit moet-
en binden. Dit wordt ook wel vergeleken met een slot (het eiwit) en een sleutel (de 
chemische stof), waarbij het kan zijn dat de sleutel het slot moet openmaken (her-
stellen van de functie van het eiwit) of het slot juist moet blokkeren (een overactief 
eiwit moet remmen). Als er een aantal stoffen gevonden of gemaakt zijn, worden die 
in verschillende lab experimenten getest, voordat een selectie van de meest veelbelo- 
vende middelen in diermodellen worden getest. Dit wordt gedaan om vast te stellen 
of de stof in een complex model goed werkt en veilig is om uiteindelijk in mensen 
getest te kunnen worden. Als in deze proeven goede resultaten behaald zijn, door-
loopt het beste middel een aantal opeenvolgende klinische studies, waarbij gebruik 
van het middel bij o.a. gezonde volwassenen en specifieke groepen (volwassen) pa-
tiënten onderzocht wordt, voordat het medicijn goedgekeurd kan worden voor ge- 
bruik. De periode van begin van het onderzoek tot het goedkeuren van een medicijn 
bestrijkt gemiddeld 12-15 jaar. Maar omdat kinderen niet zomaar kleine volwas- 
senen zijn, is er nog extra onderzoek nodig voordat een goedgekeurd medicijn bij 
kinderen, laat staan zuigelingen, toegepast kan worden. 
Ontwikkeling van nieuwe doelgerichte medicijnen tegen MLL-herschikte acute 
lymfatische leukemie bij zuigelingen
Omdat er dringend iets gedaan moet worden aan de prognose van zuigelingen met 
MLL-herschikte ALL, hebben we een andere benadering gekozen. In hoofdstuk 2 van 
dit proefschrift hebben we meer dan 3500 medicijnen, die eerder zijn goedgekeurd 
en gebruikt worden voor de behandeling van verscheidene ziektes, getest op 
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geïsoleerde leukemiecellen van zuigelingen en oudere kinderen. Hiermee hoopten 
we een aantal middelen te vinden die de leukemiecellen kunnen doden en mogelijk 
geschikt zouden zijn als medicijn tegen MLL-herschikte ALL bij zuigelingen. Omdat 
deze middelen al eerder uitgebreid getest zijn in volwassenen, verwachtten we dat 
de overgang van een nieuw middel uit onze studies, naar daadwerkelijke toepassing 
in de kliniek, drastisch verkort zou kunnen worden. Onze lab experimenten wezen 
uit dat de stof 7-ethyl-10-hydroxycamthotecin (SN-38) bij lage concentraties zeer 
effectief leukemie cellen kon doden. Verder onderzoek in muismodellen wees uit 
dat een voorlopermedicijn (irinotecan) dat in het lichaam omgezet wordt naar SN-
38, zeer effectief leukemiecellen in de muis kon blokkeren. Irinotecan was zelfs in 
staat om vergevorderde leukemie in muizen terug te dringen tot een niveau dat de 
leukemiecellen niet meer te detecteren waren. Hoewel de resultaten van SN-38 en 
irinotecan zeer veelbelovend zijn, is de werking van deze middelen niet specifiek: 
van snel delende cellen in het lichaam kan verwacht worden dat zij ook een bepaalde 
gevoeligheid hebben voor deze chemotherapeutica. Daarom gaat het onderzoek door 
naar middelen die specifieker op de genetische fouten in MLL-herschikte leukemie 
aangrijpen.
In hoofdstuk 3 hebben we onderzoek gedaan naar MLL-herschikte ALL cellen met 
extra RAS mutaties, wat geassocieerd wordt met een zeer slechte prognose, mede 
door verhoogde resistentie tegen de behandeling met prednison. Hiertoe hebben 
we een aantal medicijnen getest die aangrijpen op eiwitten en processen die be-
trokken zijn bij de werking van het (gemuteerde) RAS eiwit. Het was interessant 
om te zien dat chemische stoffen die de werking van het eiwit MEK blokkeren, 
effectief leukemiecellen konden doden in lab experimenten. Daarnaast ontdekten we 
dat deze MEK inhibitors de leukemiecellen gevoeliger konden maken voor predni- 
solon, de werkzame vorm van prednison. Vanwege deze veelbelovende resultaten, 
besloten we de meest effectieve MEK inhibitor (trametinib) verder te onderzoeken 
in een muismodel. In hoofdstuk 4 beschrijven we de experimenten. Hoewel we geen 
overduidelijke remming van de leukemiecellen zagen in de muizen die behandeld 
werden met trametinib, vonden we toch interessante aanknopingspunten. Zo be-
vatte het beenmerg van een aantal behandelde muizen nauwelijks nog leukemiecel-
len. Ook was de infiltratie van het centrale zenuwstelsel door de leukemiecellen te- 
ruggedrongen als gevolg van de behandeling met trametinib. Verder onderzoek naar 
een combinatie behandeling met trametinib en prednisolon zou van toegevoegde 
waarde kunnen zijn. 
Hoofdstuk 5 beschrijft het onderzoek naar middelen die directer aangrijpen op pro-
cessen waarbij het MLL eiwit betrokken is. Hiervoor zijn 84 verschillende medi- 
cijnen (deels nog in ontwikkeling) getest voor hun remmende werking op leukemie-
cellen. Neplanocin en 3-deazaneplanocin (DZNep), twee middelen die erg op elkaar 
lijken, kwamen hieruit naar voren als interessant optie, mede door hun mogelijke 
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werkingsmechanisme. Hoewel beide middelen effectief leukemiecellen remden, en 
geen gezonde beenmergcellen, was dit niet specifiek voor MLL-herschikte leukemie. 
Daarnaast wees verder onderzoek in een muismodel uit dat DZNep op zichzelf niet in 
staat was om leukemie te remmen. Recente onderzoeken naar DZNep als onderdeel 
van combinatiebehandeling tegen andere vormen van kanker, leverden veelbeloven-
de resultaten op. Dit biedt aanknopingspunten om de mogelijkheden voor DZNep in 
combinatie met andere medicijnen tegen MLL-herschikte leukemie te onderzoeken. 
Conclusie
In dit proefschrift hebben we verschillende mogelijke therapieën tegen MLL-her-
schikte ALL bij zuigelingen onderzocht, en SN-38 gevonden als veelbelovend mid-
del. Naar verwachting zal onderzoek naar specifieke(re) medicijnen tegen dit type 
leukemie zich focussen op het blokkeren van de processen rondom het MLL-fusie 
eiwit. Daarbij zal de effectiviteit van deze middelen als onderdeel van combinatie-
behandelingen een grote rol spelen, en hopelijk op relatief korte termijn een be- 
langrijke bijdrage leveren aan de prognose voor zuigelingen met MLL-herschikte 
acute lymfatische leukemie.  
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en fair gaf je feedback, of het nou om de plannen in het onderzoek ging, of over de 
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admired your broad scientific knowledge, and enjoyed the dinners and “borrels”. 
Good luck with the next steps in your career. Priscilla, jij begon als mijn student, om 
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ongetwijfeld ver schoppen. Het was fijn om met je samen te werken en af en toe een 
escape room te doen. Bedankt voor al je hulp en vriendschap; en alvast veel succes 
met de afronding van jouw PhD. Pauline, jij was voor mijn een belangrijk orakel om 
gedurende mijn onderzoek mijn weg te vinden op en om het lab. Bedankt en ook jij 
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fijn samengewerkt. Bedankt voor je support en jij ook succes met de laatste loodjes. 
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het lab, met name met het opstarten van de drug library screens. Eddy, bedankt voor 
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sequencing. Miky, I enjoyed our work and discussions on drug synergism and BET 
inhibitors. Adrian, I always liked your enthusiasm for the different projects. Verder 
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en Jan, mooi om te zien dat jullie drug library screening project ook mooie resultaten 
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RAS constructen. 
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herinneringen aan de avonturen met jou en Bob in San Francisco. Bedankt daar-
voor. Isabel, discussions with you were always interesting. I think you’re a terrific 
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videogames, bordspellen, boogschieten of onderzoek ging, het was altijd leuk om 
met jou te praten. Judith, ik heb jouw kundigheid met R altijd bewonderd, naast dat 
het heel gezellig was om je erbij te hebben bij het mountainbiken. Joao, you always 
were a lot of fun to have around, whether it was having a buzz in the office, during 
soccer games or on a bike. 




len. Rui, I remember our fun soccer matches, biking and a game of pool that earned 
you a nickname. Cesca, bedankt voor de coffee-breaks, het paintballen en de lol 
tijdens borrels en etentjes. Aurélie, bedankt voor je vrolijkheid op het lab, bij het 
mountainbiken en het badmintontoernooi. Femke, bedankt voor de goede gesprek-
ken bij de koffie en de gezelligheid tijdens het fietsen. Marcel, het was altijd fijn om 
met jou te praten over poker, en te genieten van bier en lekker eten. 
Mijn eerste kamergenoten: Dicky, Rolien, Silvia, Lilian, Malou, Lisette, Arian en 
Ytje; bedankt voor de warme ontvangst. 
De analisten van de patiëntendienst wil ik graag bedanken voor hun bijdrage om 
onderzoek met primair materiaal binnen de afdeling mogelijk te maken: Jessica, 
Wilco, Susan, Lonneke, Pauline, Merel, Patty. 
Eric, Iris, Marjolein, Myrte, Ellen, Clarissa, Cees, Yvette, Jordy, Ruben, Willemieke, 
Joris, Lieke, Rosanna, Ingrid, Farhad, Linda, Lea, Theo, Cynthia, Kirsten, Yun-Lei, 
Diana, Ad, Sharon, Nicole, Noorie, Askar, Patrick, Sanne, Jasmijn, Eva, Eva, Jenny, 
Daria, Magban, Elnaz; het was fijn om jullie als collega te hebben. 
Ook wil ik de groepsleiders van lab kindergeneeskunde bedanken. Monique, be-
dankt dat je de secretaris van mijn leescommissie wilde zijn. Ook dank voor al je 
vragen en suggesties tijden de vele werkbesprekingen. Jules, Maarten, Janneke en 
Wendy, bedankt voor de prettige discussies en feedback tijdens alle meetings. Ik 
wens jullie allen het beste. 
Mijn collega’s bij Janssen Vaccines wil ik bedanken voor de warme ontvangst; de 
Molecular Bioassays en Viral & Microbial Safety teams in het bijzonder. Graag wil 
ik Michelle, Femke en Mark bedanken voor het vertrouwen en de kansen die ze me 
hebben geboden, terwijl dit proefschrift nog in voorbereiding was. Azra, bedankt 
voor je support in aanloop naar en tijdens mijn begin bij Janssen. Fellow Geeks and 
vikings: Martijn, Saskia, Michelle, Ewoud, Gerard, Mark and Harold, I hope we can 
conquer many more obstacles together. 
Mitchell, Vincent en Bas. Ik heb altijd ontzettend veel voldoening gehaald uit de 
momenten wanneer wij als Stoelendans met muziek bezig waren, of het nou oefenen 
in Amsterdam of Alkmaar was, bij de optredens of gewoon onder het genot van 
lekker eten. Bas, ik heb jouw kennis en plezier voor alles wat met muziek te mak-
en heeft altijd bewonderd. Vince, jouw doorzettingsvermogen bij alles wat je doet 
en meemaakt heb ik veel respect voor. Je bent een topgozer. Mitch, jouw relative- 
ringsvermogen kan ik af en toe een voorbeeld aan nemen. Of het nou ging met een 
goed gesprek, een middagje jammen of tot in de kleine uurtjes gamen, je bent voor 
mij een belangrijke steunpilaar geweest. Ik ben blij dat we al zo lang buddies zijn. 
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Sebastiaan, onze etentjes en avondjes stappen waren voor mij een welkome afleiding 
en een goed moment om ervaringen uit te wisselen, of met veel plezier herinneringen 
uit Wenen op te halen. Bedankt voor je steun. 
Vero, Preya and Vali, Waiman and Lynn, thanks a lot for all the terrific food, parties 
and trips. Ruud, Patrick en Saori, Anton en Christy, Valentijn, bedankt voor de gezel-
ligheid tijdens (winter)bbq’s en verjaardagen. Azra, Sabrina, Raymond en Folkert, 
het was fijn om af en toe PhD ervaringen uit te kunnen wisselen en herinneringen op 
te kunnen halen. Maarten, Ismayil en Joeri, onze bordspelavonden waren een wel-
kome afleiding tijdens de laatste periode. 
De families Kerstjens, De Graaf en Van Offenbeek wil ik bedanken voor hun steun 
de afgelopen jaren. Paula en Peter, Jan en Béatrice, Gé en Anita, Roel en Sanne, Ivo 
en Susan, Norbert en Carmen, Rick en Emma, Jan en Erica,  bedankt voor jullie 
onvermoeibare belangstelling voor mijn onderzoek en de fijne gesprekken en ge-
zelligheid bij verjaardagen en feestjes. Ivo, het was fijn om headbangend alles af en 
toe even los te laten. Ook dank aan Adri en Annette, Lennaert en Rebecca, Gray en 
Jamillah, en de families Deij, Bleeker en De Roon. 
Het is ontzettend fijn om uit een warm nest te komen. Lieve Jeroen, Bart en Saskia, 
jullie betekenen heel veel voor me. Jullie hebben me altijd gesteund, met grappen en 
grollen, een luisterend oor en met het ophalen van herinneringen. Jeroen, samen ge-
nieten van lekker eten met een alcoholische versnapering, en met een goed gesprek, 
is altijd een welkome afleiding. Bart, onze gedeelde interesses zijn fijn om samen 
even te ontkomen aan de soms stressvolle tijden, of het nou om bordspellen, video- 
games, lekker koken of Star Wars gaat, samen met jou is het altijd top. Saskia, het is 
geweldig met jou samen katten te knuffelen, van taco’s te genieten en er voor elkaar 
te kunnen zijn als het soms even niet mee zit. Zonder jullie waren de afgelopen jaren 
een stuk zwaarder geweest. 
 
Lieve pap en mam. Ik kan moeilijk uitdrukken hoe belangrijk jullie voor me zijn en 
hoeveel jullie voor me betekend hebben. Jullie hebben me gevormd tot de persoon 
die ik nu ben. Jullie hebben me bijgestuurd op cruciale momenten om de juiste keu-
zes te maken en ik ben jullie daar ongelofelijk dankbaar voor. De afgelopen jaren 
zijn niet makkelijk geweest, maar altijd kon ik rekenen op jullie onvoorwaardelijke 
steun. Zonder jullie was dit proefschrift er niet geweest. 
Lieve Jody, bedankt dat je er al die tijd voor me geweest bent. Er zijn talloze mo-
menten dat je me motiveerde en aan wist te sporen om door te zetten, juist als het 




achter me. Het is voor ons allebei een mooie maar ook pittige periode geweest. Jouw 
liefde, geduld en pragmatische instelling waren voor mij onmisbaar bij het afronden 
van dit proefschrift. Ik kijk uit naar onze toekomst samen. 
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